HilleVax
MA - BostonBiotechnology
Focus: HilleVax is a Boston-based public biotech focused on developing a norovirus vaccine to address gastroenteritis, a significant unmet medical need in infectious diseases.
Profile data last refreshed 15h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
0
About HilleVax
AI assessmentNot HiringNo open roles listed right now. Follow HilleVax to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
4 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
Placebo
GastroenteritisClinical Trials (1)
NCT06007781Safety and Immunogenicity of HIL-214 in Healthy Japanese Infants
Phase 1Help build intelligence for HilleVax
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.